HomeAI · summaries
Storia in 9 fonti
Indian pharma firms may yet survive Trump's 200% tariff bombshell
Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited. India's cost advantage, America's dependence on imported generics and lengthy US factory approval timelines could make large-scale manufacturing shifts difficult despite Trump's reshoring push.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
timesofindia.indiatimes.com
Trump announces 0% tariff on generic medicines for two years; 200% thereafter
US President Donald Trump on Tuesday announced a phased tariff regime on imported generic medicines, saying they will continue to enter the United States duty-free for two years…
- ·
economictimes.indiatimes.com
Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%
Trump has been pressuring drugmakers through his most-favored-nation drug pricing policy to lower prices to what people pay in other high-income countries.
- ·
hindustantimes.com
US to impose steep tariffs on generic medicine imports from Aug 2028
US to impose steep tariffs on generic medicine imports from Aug 2028
- ·
thehindubusinessline.com
US to impose 100% tariffs on generic medicine imports from Aug 2028
US President Donald Trump on Wednesday announced steep tariffs on imported generic medicines from August 2028, asserting that the move was aimed at onshoring the manufacturing of…
- ·
france24.com
Trump announces 100% tariffs on imported generic pharmaceutical drugs
US President Donald Trump announced a 100% tariff on imported generic pharmaceutical drugs on Tuesday. The tariff, which aims to bolster US pharmaceutical production, is set to go…
- ·
Why these 8 stocks including Pharma majors will remain in focus on today following Trump’s tariff announcement
Maruti Suzuki’s price hike, Anant Raj demerger, Aurobindo Pharma getting nod for bio similar, Anupam Rasayn open offer to Bliss GVS shareholders
- ·
benzinga.com
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plan
Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.
- ·
Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028
Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption…
- ·
newsbytesapp.com
Trump threatens tariff on generic medicines: Should India be worried?
US President Trump announced a two-year tariff exemption for imported generic medicines, warning of steep 200% duties if production doesn't shift to the US afterward.
- ·
swissinfo.ch
Trump’s 100% Generic Drug Duty Threatens US Low-Cost Supply
(Bloomberg) -- Generic drug manufacturers will have two years to move production to the US or face a 100% import duty from August 2028, President Donald Trump said, threatening…
- ·
0, 100, 200: How Trump's latest generic medicines tariffs could affect India
Indian drugmakers export around $9-10 billion worth of generic medicines to the American market every year. | India News
- ·
Pharma stocks bleed after Trump announces up to 200% tariff on generic drugs; Aurobindo, Sun Pharma & Cipla slide over 3%
Pharmaceutical stocks came under pressure on Wednesday after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, raising concerns over the…
- ·
Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm
Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After…
- ·
Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?
The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one hundred percent, eventually reaching…
- ·
Trump’s 100% generic drug duty threatens US low-cost supply
President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…
- ·
200% Trump tariff shock? India’s cheap pills may still beat US rivals
US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage…
- ·
Indian pharma firms may yet survive Trump's 200% tariff bombshell
Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…
- ·
Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investors
Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be…
- ·
Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive
In a blow to India’s pharmaceutical industry, the Donald Trump administration has announced up to 200% tariffs on generic drugs that will be applicable in the coming years.
- ·
independent.co.uk
Trump announces plan for 200% tariffs on imported generic drugs
Under the plan, announced on Truth Social, generic drugs imported into the U.S. would remain tariff-free for two years beginning Aug. 1